Confo Therapeutics enters into drug discovery collaboration with Lundbeck
Ghent, Belgium – September 26, 2017
Confo Therapeutics, an emerging drug discovery company, today announced that it has entered into a drug discovery collaboration with H. Lundbeck A/S, a global pharmaceutical company specializing in psychiatric and neurological disorders. The goal of the collaboration is to deploy the Company’s proprietary Confo® technology to discover novel, small molecule therapeutic compounds acting upon two G-protein coupled receptors (GPCRs). .
Under the terms of the agreement, Lundbeck has an option to an exclusive license to develop, manufacture and commercialize the compounds resulting from the collaboration. Confo Therapeutics will receive up to a total of €5 million in technology access fees and research funding during the initial 2 year period of the collaboration, and is eligible to receive further milestone payments, as well as tiered royalties on the annual net sales of any products resulting from the collaboration.
Commenting on the agreement, Dr. Cedric Ververken, CEO, said: “We are delighted to partner with Lundbeck on these particular targets, given their leading expertise in neuroscience research and development. The agreement is a further endorsement of the power and applicability of our proprietary Confobody technology and the Company’s strategy of combining selected pharma partnerships with the development of a proprietary product pipeline.”
Kim Andersen, Senior Vice President of Research for H. Lundbeck A/S, commented: “The collaboration with Confo Therapeutics will allow Lundbeck to work on GPCRs that we have not been able to address previously. This novel technology will provide high quality chemical starting points, together with structural information, for this important target class and enable us to initiate new projects in our preclinical portfolio for schizophrenia, depression, AD and PD and ultimately bring new products to the market benefiting patients with neurological and psychiatric diseases.”
Confo Therapeutics was co-founded in 2015 by VIB, VUB and Capricorn Venture Partners with the support of MINTS, PMV, QBIC, SOFI and V-Bio Ventures. Confo Therapeutics is a drug discovery company building a portfolio of first-in-class programs based on its proprietary Confo® technology, using antibody fragments or “Confobodies” to lock inherently unstable functional conformations of GPCRs as a superior starting point for drug discovery.
G-protein coupled receptors (GPCRs) are attractive drug targets in the treatment of many different conditions, playing an essential part in numerous life processes and influencing diseases. GPCRs are flexible signaling switches located in the cell membrane and pass outside signals into the cell through conformational changes.